Simvastatin Accord 10 mg film - coated tablets Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

simvastatin accord 10 mg film - coated tablets

accord healtcare limited, uk - Симвастатин - 10 mg film - coated tablets

Simvastatin Accord 20 mg film - coated tablets Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

simvastatin accord 20 mg film - coated tablets

accord healtcare limited, uk - Симвастатин - 20 mg film - coated tablets

Simvastatin Accord 40 mg film - coated tablets Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

simvastatin accord 40 mg film - coated tablets

accord healtcare limited, uk - Симвастатин - 40 mg film - coated tablets

Terazosin Accord  2 mg tablets Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

terazosin accord  2 mg tablets

accord healtcare limited, uk - 2 mg tablets

Mycophenolate Mofetil Accord  250 mg capsules Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

mycophenolate mofetil accord  250 mg capsules

accord healtcare limited, uk - Микофенолата мофетил - 250 mg capsules

Irbesartan Accord 150 mg film-coated tablets Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

irbesartan accord 150 mg film-coated tablets

accord healtcare limited, uk - 150 mg film-coated tablets

Cytarabin Accord 100 mg/ml solution for injection or infusion Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

cytarabin accord 100 mg/ml solution for injection or infusion

accord healtcare limited, uk - Цитарабин - 100 mg/ml solution for injection or infusion

Ondansetron Accord 2 mg/ml Solutiotion for injection or infusion Bulgarija - Bulgaru - Изпълнителна агенция по лекарствата

ondansetron accord 2 mg/ml solutiotion for injection or infusion

accord healtcare limited, uk - Ондансетрон - 2 mg/ml solutiotion for injection or infusion

Sorafenib Accord Unjoni Ewropea - Bulgaru - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Антинеопластични средства - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Plerixafor Accord Unjoni Ewropea - Bulgaru - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.